Cargando…
Unintended Regulatory Caused Early Death—A Difficult Endpoint in Cancer Patient Care and Treatment
SIMPLE SUMMARY: This is a position paper by a clinical oncologist. It voices concerns about political decision making and regulatory time frames for drug availability, both of which are critical for patient care in life-threatening diseases such as cancer. ABSTRACT: The pharmacological armory agains...
Autor principal: | Berdel, Wolfgang E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005202/ https://www.ncbi.nlm.nih.gov/pubmed/33810203 http://dx.doi.org/10.3390/cancers13061457 |
Ejemplares similares
-
Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
por: Kemp, Robert, et al.
Publicado: (2017) -
Activation of Investigator-Initiated Clinical Trials with a Pharmaceutical for Cancer Patients before and after Post-Millennial Changes of Regulations in Germany and Europe
por: Berdel, Wolfgang E.
Publicado: (2022) -
Access Denied? The Unintended Consequences of Pending Drug Pricing Rules
por: Kaplan, Alan, et al.
Publicado: (2022) -
Quality of Life in Low-Risk MDS: An Undervalued Endpoint
por: Heyrman, Bert
Publicado: (2022) -
Unintended consequences of the potential phase-out of gamma irradiation
por: Chou, Jacquelyn W, et al.
Publicado: (2018)